BOSH MIYANING BIRLAMCHI O'SMALARINI TASHXISLASH VA DAVOLASHGA ZAMONAVIY MULTIMODAL YONDASHUVLAR

Maqola yon paneli

pdf (inglizcha)
Nashr qilingan: 2026-01-05
DOI: https://doi.org/10.66073/researchfocus.v4i12.1928
Kalit so‘zlar:
miya o‘smalari, gliomalar, nur terapiyasi, multimodal davolash, stereotaktik radiokhirurgiya

Maqolaning asosiy mazmuni

Mamadaliev Abduraxmon Mamatkulovich
Samarqand davlat tibbiyot universiteti huzuridagi Neyroxirurgiya va neyroreabilitatsiya ixtisoslashtirilgan ilmiy-amaliy markazi

Abstrak

Birlamchi miya o‘smalari klinik va ijtimoiy jihatdan muhim bo‘lgan geterogen kasalliklar guruhini tashkil etadi. Ushbu o‘smalar orasida neyroepitelial, ayniqsa glial o‘smalar yetakchi o‘rinni egallaydi va ular agressiv biologik xususiyatlari, yuqori qaytalanish darajasi hamda cheklangan uzoq muddatli yashash ko‘rsatkichlari bilan tavsiflanadi. Zamonaviy diagnostika asosan magnit-rezonans tomografiya va kompyuter tomografiyasiga asoslanadi, shu bilan birga MRI va pozitron-emission tomografiyani birlashtirgan gibrid usullarga qiziqish ortib bormoqda. Markaziy asab tizimi o‘smalarini davolashda multimodal yondashuv qo‘llanilib, unga neyroxirurgik rezeksiya, nur terapiyasi, kimyoterapiya va immunoterapevtik usullar kiradi. Nur terapiyasi malign miya o‘smalarini davolashda asosiy usul bo‘lib qolmoqda va dozaning ilmiy asoslangan fraksiyalanishi o‘sma nazoratini ta’minlab, nojo‘ya ta’sirlarni kamaytiradi. Stereotaktik radiokhirurgiya va neyronavigatsiyaning rivojlanishi davolash aniqligi va samaradorligini sezilarli darajada oshirdi. Shunga qaramay, yuqori darajali glial o‘smalarda prognoz hanuz noqulay bo‘lib, yangi va individuallashtirilgan davolash strategiyalarini ishlab chiqish zaruratini ko‘rsatadi.

Maqola tafsilotlari

Nashr

Jild 4 Nomeri 12 (2025): Research Focus International Scientific Journal. 4-tom, 12-son (2025)

Bo'lim

14.00.00 – Tibbiyot fanlari
Creative Commons litsenziyasi

Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.

Qanday iqtibos keltirish kerak

BOSH MIYANING BIRLAMCHI O’SMALARINI TASHXISLASH VA DAVOLASHGA ZAMONAVIY MULTIMODAL YONDASHUVLAR. (2026). Research Focus International Scientific Journal, 4(12), 199-203. https://doi.org/10.66073/researchfocus.v4i12.1928

Adabiyotlar

Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., … Ellison, D. W. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology, 23(8), 1231–1251. https://doi.org/10.1093/neuonc/noab106

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., … Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330

Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States. Neuro-Oncology, 21(Suppl 5), v1–v100. https://doi.org/10.1093/neuonc/noz150

Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., … Buckner, J. C. (2016). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy. Journal of Clinical Oncology, 31(3), 268–275. https://doi.org/10.1200/JCO.2012.45.6912

Pearce, M. S., Salotti, J. A., Little, M. P., McHugh, K., Lee, C., Kim, K. P., … Parker, L. (2012). Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours. The Lancet, 380(9840), 499–505. https://doi.org/10.1016/S0140-6736(12)60815-0